Creatinine reduction ratio: a useful marker to identify medium and high-risk renal transplants

Transplantation. 2010 Jan 15;89(1):97-103. doi: 10.1097/TP.0b013e3181be3dd1.

Abstract

Introduction: Delayed graft function (DGF) has a major impact on long-term renal transplant survival. However, it is a diagnosis made retrospectively with little opportunity to modify treatment protocols. A classification based on creatinine reduction ratio between days 1 and 2 (CRR2) suggests that patients with CRR2 less than or equal to 30% (nondialysis requiring DGF [ND-DGF]) have similar outcomes to those with dialysis-requiring delayed graft function (D-DGF). We retrospectively applied this definition in our cohort of patients to examine outcomes.

Methods: We studied the association between CRR2 and graft outcomes in all 367 patients transplanted between 1996 and 2004 at our center. Patients were divided into the following three groups: IGF (immediate graft function; CRR2 >30%), D-DGF, and ND-DGF. Mean follow-up was 4.2 years.

Results: IGF accounted for 36% of patients, D-DGF for 22%, and ND-DGF for 42%. CRR2 was inversely correlated with serum creatinine on days 7, 30, 90, and 365 (r ranging from -0.65 to -0.22, P<0.001). Graft survival at 5 years was 98% (IGF), 74% (D-DGF), and 89% (ND-DGF). There was a significant difference in graft survival between IGF and D-DGF (P<0.001) and IGF and ND-DGF (P=0.005). In a multivariate analysis adjusting for recipient age and sex, donor age and sex, and human leukocyte antigen mismatch, graft failure was 2.4 times more likely to occur in patients with D-DGF than those with ND-DGF(P=0.02).

Conclusions: Our study shows CRR2 influences long-term graft outcomes. Unlike the original description, patients with ND-DGF carry an intermediate risk and perhaps should be considered on day 2 for alternative treatment protocols.

MeSH terms

  • Adult
  • Biomarkers / blood
  • Cohort Studies
  • Creatinine / blood*
  • Delayed Graft Function / epidemiology
  • Delayed Graft Function / physiopathology
  • Drug Therapy, Combination
  • Female
  • Graft Rejection / epidemiology
  • Graft Rejection / physiopathology*
  • Graft Survival / immunology
  • Graft Survival / physiology
  • Histocompatibility Testing
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation / immunology
  • Kidney Transplantation / mortality
  • Kidney Transplantation / physiology*
  • Kidney Transplantation / statistics & numerical data
  • Likelihood Functions
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Retrospective Studies
  • Risk Factors
  • Risk Reduction Behavior
  • Survival Rate
  • Survivors
  • Tissue Donors / statistics & numerical data
  • Treatment Failure

Substances

  • Biomarkers
  • Immunosuppressive Agents
  • Creatinine